Background -Limited information is available regarding the treatment and outcome of dogs with epitheliotropic lymphoma. The disease typically has a poor prognosis.
Introduction
Epitheliotropic lymphoma (EL) is an uncommon form of lymphoma in dogs, representing 3-8% of canine lymphoma and <1% of canine cutaneous tumours. 1 The aetiology for this malignancy in dogs is unknown. 2 The tumour tends to occur in the epidermis, superficial dermis and periadnexally, although oral mucosal and mucocutaneous forms have been described. [2] [3] [4] [5] [6] [7] [8] [9] Canine EL is typically a tumour of T lymphocytes, with the CD3 + and CD4-/CD8+ phenotype most commonly expressed. 3, 8, 10 The disease tends to occur in older dogs (median age 10-12 years), 2, 3, 6, 8, 10 with no obvious gender or breed predilection, although some authors have reported that boxers and cocker spaniels may be over-represented. 2, 10 Canine EL has a poor prognosis; however, in contrast to canine multicentric lymphoma, the prognostic factors that affect survival, either with or without treatment intervention, are not well understood. 2, 5, 11 The disease is challenging to treat, with variable response rates and a short duration of response typically reported with various systemic therapies including linoleic acid, lomustine (CCNU), masitinib, PEGylated l-asparaginase, PEGylated liposomal doxorubicin, retinoids and VDC-1101. 1, 7, [11] [12] [13] [14] [15] [16] The overall response rate (ORR) reported for all therapies is from 42 to 83% for a median response duration of from 37.5 to 106 days. The reported mean and median survival times with various forms of treatment range from a few months to 2.1 years. 2, 5, 6, 15, 16 A standard of care for the treatment of EL has not yet been established; however, systemic chemotherapy (particularly with single-agent CCNU with or without prednisolone) is a common therapeutic approach. 1, 6, [11] [12] [13] 17, 18 Multi-agent chemotherapy protocols based on standard lymphoma therapy, with increased emphasis on CCNU and other alkylating agents are also used in veterinary oncology referral practices.
The most important prognostic factors for canine lymphoma are the extent of disease (stage), the absence or presence of systemic signs (substages a and b, respectively) and immunophenotype. [19] [20] [21] [22] [23] Higher stage (e.g. stage V), substage b and T-cell immunophenotype have been associated with shorter remission and survival times. Using this scheme, cutaneous lymphoma is extra nodal and, therefore, stage V. In humans, epitheliotropic lymphoma progresses through three apparent clinical stages: pre-mycotic, mycotic and tumour stage, with the presence of tumour stage (nodules or masses) conferring a worse prognosis. 24 Clinical staging of EL has not been well-established in dogs.
The primary purpose of this retrospective study was to characterize the clinical course of disease and to identify prognostic factors in a relatively large number of dogs with histopathological features consistent with EL. The secondary aim was to assess the clinical outcomes in dogs that were treated.
Materials and methods
The medical record databases for the Animal Referral Hospital in Sydney and Veterinary Oncology Consultants in Wauchope (both NSW, Australia) from October 2003 to August 2015 were searched to identify records for dogs with EL. Dogs were included in the study if they had histopathological features consistent with EL and a minimum follow-up time of three months (unless confirmed relapse or death occurred during that period). Histology slides were reviewed to determine tumour type and, when available, CD3 and CD79a immunostaining. A histological diagnosis consistent with EL in this study was characterized by neoplastic lymphocyte infiltration exclusively in the epidermis including tropism for hair follicles and sweat glands, with some samples showing Pautrier's microabscesses (collection of neoplastic lymphocytes around cutaneous dendritic cells). 10 Any equivocal cases were excluded. For each eligible dog, signalment (age, sex, breed), body weight, histopathological findings (including CD3 and/or CD79a immunophenotype when available), lymphoma substage [a (asymptomatic) or b (constitutional signs)], tumour stage (premycotic, mycotic or tumour) when available, tumour location (cutaneous, mucosal or mucocutaneous), number of lesions (solitary or multiple), duration of lesions before a histological diagnosis was made (weeks), extent of lymph node involvement (none, single, locoregional, generalized or distant) and measurable disease (yes or no) were recorded.
All dogs were staged by physical examination, calliper measurement of EL lesions, and palpation of all peripheral lymph nodes, liver and spleen. Thoracic radiography and/or abdominal ultrasonography findings (when performed) were recorded.
Treatment details were recorded including surgery [margins (complete, incomplete or unknown)], radiation therapy, retinoids, safflower oil, prednisolone and chemotherapy {single-agent CCNU, VELCAP-EL combination chemotherapy protocol [VELCAP-EL is derived from vincristine (v), L-asparaginase (EL), cyclophosphamide (C), Adriamycin (doxorubicin) (A) and prednisolone (P); EL is for epitheliotropic lymphoma], other multiple agent chemotherapy or other single-agent chemotherapy}. The dosages and schedule for VELCAP-EL are provided in Table S1 . For dogs receiving VELCAP-EL combination chemotherapy protocol and single-agent CCNU, the highest toxicity score [with reference to VCOG-CTCAE (Veterinary cooperative oncology group -common terminology criteria for adverse events) v1.1 criteria 25 ] and nature of the toxicity (haematological and gastrointestinal toxicities) were recorded.
For dogs with measurable disease, the best response to therapy was recorded where available according to response evaluation criteria for peripheral nodal lymphoma in dogs. 26 Complete remission (CR) was defined as resolution of all evidence of disease; partial remission (PR) was defined as ≥30% reduction in size of measurable lesions; stable disease (SD) was defined as <30% reduction or <20% increase in size of measurable lesions and no appearance of new lesions; and progressive disease (PD) was defined as ≥20% increase in size of measurable lesions or appearance of new lesions. The overall response rate (ORR) was defined as the number of dogs achieving either a CR or PR, compared to the number of dogs treated. For dogs with solitary lesions, the number of days until development of new lesions or metastasis was recorded. If the dog did not develop a new lesion or metastasis, the number of days the dog was alive with a solitary lesion was utilized. Survival time was evaluated with the end-point being death due to any cause. The day of histological diagnosis was considered to be Day 1. Dogs were censored from survival analysis at the last day of contact if still alive or if they were lost to follow-up. The Kaplan-Meier product limit method was used to estimate the median survival time (MST) and the one, two and three year survival percentage.
Cox regression analysis was used to evaluate the effect on survival time of tumour location (cutaneous versus mucosal and mucocutaneous), solitary versus multiple lesions, age (continuous), sex (male versus female), body weight (continuous), lymphoma substage (a versus b), tumour stage (premycotic versus mycotic versus tumour) and treatment used (surgery; retinoids; safflower oil; prednisolone; and chemotherapy). Chemotherapy protocol types (CCNU versus VELCAP-EL versus other multiple agent chemotherapy) also were evaluated.
All factors were initially evaluated separately for univariate statistical significance. Any factor with P ≤ 0.1 on univariate analysis was included in multivariate analysis using Cox forward logistic regression. For the final analysis, values of P < 0.05 were considered significant. Chi-square methods were used to compare CR rates between dogs treated with VELCAP-EL and dogs treated with CCNU. Pearson correlation was used to assess the relationship between age and survival time in dogs with solitary mucocutaneous and mucosal (McM) EL. A range of analyses evaluating dogs with McM lesions and those with cutaneous lesions was undertaken. Statistical analyses were performed using the software package SPSS 10 (Statistical Analytical Software; Chicago, IL, USA).
Results
One hundred and forty eight dogs met the inclusion criteria. The median age was 11 years (range 2-18 years of age). Sixty were males (46 castrated) and 88 were females (86 spayed). There were 40 breeds included, with cross-bred dogs being most common (n = 35). The only breeds with six or more dogs represented were golden retrievers (20) , Border collies (9), beagles (8) , cocker spaniels (6), Labrador retrievers (6) and Maltese terriers (6 Table S2 .
On multivariate analysis of the entire group, location (cutaneous versus mucosal versus mucocutaneous locations) (P < 0.001) and presence of multiple lesions versus solitary lesions (P < 0.001) were the only independent prognostic factors determined.
There was no significant difference in survival time between the mucosal group and the mucocutaneous group (mucocutaneous location versus mucosal location, P = 0.494). However, for each of these groups survival time was significantly different for the cutaneous group (cutaneous versus mucocutaneous location P < 0.001; and cutaneous versus mucosal location P = 0.001). Therefore, further analyses were performed for dogs with tumours with a cutaneous location.
Cutaneous lesions
Eighty dogs had cutaneous disease only. Eight (10%) of these dogs had solitary lesions and 72 (90%) had multiple lesions. The median age was 10.5 years (range 1-16 years of age). Thirty were males (20 castrated) and 50 were females (48 spayed). There were 30 breeds included, with cross-bred dogs being most common (n = 19). The only breeds with six or more dogs represented were golden retrievers (8) , Labrador retrievers (6), Border collies (5) and beagles (5 
Follow-up
Median survival time was 130 days (range 5-2,198 days, eight dogs censored). Seventy two of 80 (90.0%) dogs were confirmed dead (44 of known EL, 11 of causes believed not to be EL-related and 17 where cause of death was unknown). Of the eight remaining dogs, seven (8.7%) were lost to follow-up (median 281 days, range 85-839 days) and one (1.3%) was still alive at 646 days.
Treatment
Nine of 80 (11.3%) dogs underwent surgery. Of six dogs with solitary lesions, three were completely excised, two incompletely excised and one was excised with margins not described. Of three dogs with multiple lesions, one had all lesions completely excised, one had incomplete excision and one had excision with margins not described. Two of the nine dogs that underwent surgery also received retinoid treatment (22.2%) and three (33.0%) received chemotherapy after surgery. Table 1 .
Response to treatment and outcomes Seventy one of 80 (88.8%) dogs had measurable disease. Of these, 52 were evaluated for a response to therapy. Of 10 dogs with measurable disease treated with CCNU (with or without prednisolone), one (10.0%) dog obtained CR, six (60.0%) obtained PR, one (10.0%) had SD and two (20.0%) had PD. The ORR was 70.0%. MST was 130 days (range 34-281 days, two censored). Of 29 dogs with measurable disease treated with VELCAP-EL protocol, 11 (37.9%) dogs obtained CR, 12 (41.4%) obtained PR, five (17.3%) had SD and one (3.4%) had PD. The ORR was 79.3%. MST was 207 days (range 23- On univariate analysis, use of chemotherapy (P = 0.006) and presence of multiple lesions (P = 0.019) were found to be potentially associated with survival time. On multivariate analysis, both factors retained statistical significance as independent predictors of survival time (P < 0.001 for both).
Thirty one dogs received no chemotherapy; all had died at the end of data collection. Median survival was 64 days (range 5-2,124 days, 95% CI 45-83 days) with 12.9% alive at one year and 9.7% alive at two and three years after diagnosis. Forty nine dogs received chemotherapy, of which eight were censored. Median survival was 207 days (range 23-2,198 days, 95% CI 140-274 days) with 32.6% alive at one year, 20.0% alive at two years and 16.0% alive at three years after diagnosis.
Seventy two dogs had multiple lesions, of which seven were censored. Median survival was 104 days (range 5-2,079 days, 95% CI 66-142 days) with 23.2% alive at one year, and 13.1% alive at two and three years after diagnosis. Eight dogs had solitary lesions, of which one was censored. Median survival was 231 days (range 136-2,198 days, 95% CI 151-311 days) with 42.8% alive at one year, and 28.6% alive at two and three years after diagnosis (Figure 1) .
On the basis of these data, further analysis was performed to determine the effect of chemotherapy in 72 dogs that had multiple cutaneous lesions and this was significant on multivariate analysis (P < 0.001). There were 25 dogs that received no chemotherapy, of which none were censored. Median survival was 53 days (range 5-2,124 days, 95% CI 45-83 days) with 12.9% alive at one year, 9.7% alive at two years and 4.0% alive at three years after diagnosis. There were 47 dogs that received chemotherapy, of which seven were censored. Median survival was 188 days (range 23-2,198 days, 95% CI 131-245 days) with 31.2% alive at one year, 18.3% alive at two years and 13.7% alive at three years after diagnosis ( Figure 2) .
In 72 dogs with multiple cutaneous lesions, the effect of retinoid treatment on survival also was found to be significant on multivariate analysis (P = 0.001) and therefore independent of whether dogs received chemotherapy. Eighteen dogs received retinoid treatment (12 received retinoids with chemotherapy, five received retinoids alone and one received retinoids with prednisolone) of which three were censored. Median survival was 251 days (range 34-1,290 days, 95% CI 0-570 days) with 48.2% alive at one year, 18.3% alive at two years and 9.2% alive at three years after diagnosis. Fifty four dogs received no retinoid treatment, of which four were censored. Median survival was 98 days (range 5-2,079 days, 95% CI 74-122 days) with 15.3% alive at one year, 10.9% alive at two years and 7.3% alive at three years after diagnosis (Figure 3 ).
Response to chemotherapy was assessable in 44 of 47 dogs with multiple cutaneous lesions that received chemotherapy. The ORR to treatment with VELCAP-EL combination chemotherapy and single-agent CCNU were 79.3% and 70.0%, respectively. The MST with VELCAP-EL combination chemotherapy and single-agent CCNU Duration of survival in days were 207 days and 130 days, respectively. Achievement of CR was associated with increased survival time on multivariate analysis (P = 0.001). Fourteen dogs achieved CR, of which two were censored. Median survival was 401 days (95% CI 363-439 days) with 63.5% alive at one year and 31.7% alive at two years after diagnosis. Nineteen dogs achieved PR, of which four were censored. Median survival was 130 days (95% CI 14-246 days) with 18.7% alive at one year and 9.4% alive at two years after diagnosis. Eleven dogs had no response to therapy (SD and PD), and all had died at study conclusion. Median survival was 110 days (95% CI 55-165 days) with 9.1% alive at one and two years after diagnosis (Figure 4) .
The effect of type of chemotherapy treatment (VEL-CAP-EL versus CCNU versus other multiple agent chemotherapy) was not associated with survival time (P = 0.634). Dogs receiving VELCAP-EL showed a trend toward being more likely to achieve CR than dogs receiving CCNU. One of 10 (10%) dogs treated with CCNU achieved CR with an overall survival of 281 days and 11 of 29 (37.9%) dogs treated with VELCAP-EL achieved CR with a MST of 401 days, although the CR rates were not significantly different (P = 0.102).
Mucocutaneous and mucosal (Mcm) location
The median age was 11 years (range 2.5-18 years of age). Thirty were males (26 castrated) and 38 were females (all spayed). There were 24 breeds included, with cross-bred dogs being most common (n = 16). The only breeds with four or more dogs represented were golden retrievers (12), cocker spaniels (5), Border collies (4) and Maltese terriers (4). Median body weight was 18.2 kg (range 2.9-51.3 kg).
Sixty (88.2%) dogs were in lymphoma substage a and eight (11.8%) dogs were in substage b. Eight (13.8%) dogs had premycotic lesions, 26 (44.8%) had mycotic lesions and 24 (41.4%) had tumour lesions. Clinical stage could not be determined for 10 dogs from the records.
Lesions were present for a median of four weeks (range 0-52 weeks) before a diagnosis was confirmed on histological examination of a tissue biopsy (information available for 55 dogs). Lymph nodes were normal on palpation, cytological evaluation, biopsy and/or imaging in 38 of 60 (63.3%) dogs. Nodal involvement was suspected (lymphadenopathy on palpation or imaging) or confirmed (cytology or biopsy) in 22 of 60 (36.7%) dogs; 11 single node, eight locoregional, two generalized and one distant. Lymph node assessment was not recorded for eight (11.7%) cases.
Thoracic radiography was performed in 40 of 68 (58.8%) dogs and was considered normal in 35 dogs, abnormal (pleural effusion, pulmonary nodules and/or evidence of lymph node enlargement) in three dogs, and equivocal in two dogs. Abdominal ultrasonography was performed in 29 of 68 (42.7%) dogs, and was considered normal in 26 dogs and abnormal [imaging (splenomegaly and/or intraabdominal lymphadenopathy) and/or via cytological confirmation of lymphoma] in three dogs.
Of the 52 dogs with solitary lesions, 15 (28.8%) developed new lesions (10 dogs), nodal metastasis (four dogs) or systemic metastasis (one dog) at a median of 275 days (range 9-1,190 days); and 37 (71.2%) dogs did not develop additional lesions for a median follow-up time of 501 days (range 32-2,207 days).
Follow-up
The median survival time was 491 days (range 30-2,992 days, 24 censored). Forty four (64.7%) dogs were known to be dead (20 of known EL, seven of causes not Table 2 .
EL-related and 17 where cause of death was unknown
Response to treatment and outcomes Thirty five of 68 (51.5%) dogs had measurable disease at the time systemic therapy was instituted; of these, 27 were evaluated for a response to therapy. Of three dogs with measurable disease treated with CCNU (with or without prednisolone), all three (100.0%) dogs obtained PR. No dogs obtained CR, SD or PD. The survival times for the dogs that obtained PR were 100 and 707 days (one censored at 140 days). Of 11 dogs with measurable disease treated with VELCAP-EL protocol, seven (63.6%) dogs obtained CR, three (27.3%) obtained PR, one (9.1%) had SD and none had PD. The ORR was 90.9%. MST was 281 days (range 32-1,440 days, two censored). Of two dogs with measurable disease treated with other multiple agent chemotherapy, one (50.0%) dog obtained CR and one (50.0%) dog had PD. No dogs obtained PR or SD. Survival time for the dog that obtained CR was 376 days (censored at last known follow-up) and survival time for the dog that had PD was 281 days. Of 11 dogs with measurable disease treated with prednisolone alone, two (18.1%) dogs obtained CR, three (27.3%) obtained PR, three (27.3%) had SD and six (54.6%) had PD. The ORR was 45.4%. The MST was 309 days (range 30-641 days, four censored).
Prognostic factors
For all 68 dogs with McM lesion location (24 censored) the MST was 491 days (range 30-2,992 days; 95% CI 158-824 days) and the one, two and three year survival proportions were 59.5%, 44.3% and 25.6%, respectively.
On univariate analysis, the presence of multiple lesions (P < 0.001) and increasing age at diagnosis (P = 0.001), were found to be potentially associated with survival time and were offered to multivariate analysis. On multivariate analysis, both factors retained statistical significance as independent predictors of poor survival at P = 0.015 and P = 0.020, respectively.
Sixteen dogs had multiple lesions, of which one was censored. Median survival was 241 days (range 30-1,873 days, 95% CI 156-326 days) with 6.8% alive at one year, two years and three years after diagnosis. Fifty two dogs had solitary lesions, of which 23 were censored. Median survival was 849 days (range 32-2,992 days, 95% CI 651-1,047 days) with 76.1% alive at one year, 56.0% alive at two years and 30.5% alive at three years after diagnosis ( Figure 5 ). Using Pearson correlation, there was a moderate negative correlation [r (50) = -0.374, P = 0.006] between increasing age of dogs with solitary McM EL and their survival time.
In addition, when subsets of 52 dogs with solitary lesions and 16 dogs with multiple lesions were evaluated; increasing age retained statistical significance as an independent predictor of poor survival in dogs with solitary lesions (P = 0.021, multivariate analysis) but not in dogs with multiple lesions (P = 0.717, univariate analysis).
Discussion
To the best of the authors' knowledge, this is the largest study published of dogs with clinical and histological lesions consistent with EL. The median age of affected dogs in the present study was 11 years, which is comparable to other studies. 2, 3, 6, 8, 10 However, in contrast to other studies, 2,10 which demonstrated no gender or breed predilection, our study demonstrated a slight female predilection (female:male ratio of 1.5:1) and a breed predilection for the golden retriever.
Previous studies have shown that canine EL is typically a tumour of T lymphocytes. 3, 8, 10 Our study supports these findings with 97.2% of tumours evaluated expressing CD3, none expressing CD79a and 2.8% expressing a null cell immunophenotype (negative for both CD3 and CD79a).
Three studies to date have evaluated prognostic factors for dogs affected with EL.
2,5,11 A significant survival advantage was observed in 14 dogs with oral mucocutaneous lymphoma (of which 12 had EL) that had no lymph node metastasis and had achieved CR with radiotherapy. 5 In contrast, two studies were not able to demonstrate any effect of lymph node involvement or any other parameter on response to therapy, response duration or survival. In this study, independent predictors of poor survival were having the cutaneous form of the disease (P < 0.001) and multiple lesions (P < 0.001). Different prognostic factors were identified for dogs with cutaneous versus McM disease, supporting the clinical impression that these respond differently to treatment intervention. For dogs with McM lesions, younger dogs and dogs with solitary lesions had a statistically significant survival advantage not reported previously.
2,11
Lymph node involvement as a prognostic indicator for canine EL is controversial. 5 , 11 In this study, lymph node involvement was not associated with survival times for either cutaneous or McM forms of EL.
In contrast to most other forms of canine lymphoma, the absence or presence of systemic signs (substage a and b, respectively) was not associated with survival time. In humans, the presence of advanced tumour stage (nodules or masses) confers a worse prognosis. 24 This was not found to be the case in this series of dogs.
Alkylating agents may play a role for the treatment of multicentric T-cell lymphoma. [27] [28] [29] [30] [31] Chemotherapy is not widely reported for EL in dogs, with most of the information available for CCNU. The reported ORR using CCNU for 82 dogs in two studies was 80% for approximately 100 days median duration. 7, 11 Other chemotherapy agents include: PEGylated L-asparaginase with a short PR in seven treated dogs; 12 masitinib with an ORR of 70% in 10 dogs for a median of 85 days; 1 and nine dogs treated with PEGylated liposomal doxorubicin with an ORR of 44% with three of dogs achieving CR for a median of 90 days. 15 Dacarbazine treatment was associated with CR for more than one year in one dog with localized EL. 17 VDC-1101 (a nucleotide prodrug) and prednisolone resulted in a 45% ORR in 11 dogs with cutaneous lymphoma (nine had EL) for a median of 37.5 days. 14 In general, combination chemotherapy is preferred over single-agent chemotherapy for treatment of lymphoma in people, dogs and cats. The VELCAP-EL combination protocol, described in this study, uses more alkylating agents than typical lymphoma protocols and emphasizes CCNU. In this study, the ORR in dogs with cutaneous and McM forms of EL were 79.3% and 90.1%, respectively, which compares favourably with previous reports. 1, 7, [11] [12] [13] [14] [15] [16] . However, although ORR were high, CR rates differed and those dogs achieving PR to therapy did not have the same survival advantage as those dogs achieving a CR. Only 10% of dogs that received CCNU achieved CR, compared to 38% of dogs treated with the combination protocol. A further 60% of dogs treated with CCNU and 41% of dogs treated with a multi-agent protocol achieved a PR, but the duration of that response was shorter at 4.3 months.
In this study, there was no demonstrated benefit of using chemotherapy for dogs with McM lesions or solitary cutaneous lesions. However, for dogs with multiple cutaneous lesions, and thus a poorer prognosis, the administration of any form of chemotherapy (P < 0.001) or retinoid treatment (P = 0.001) had a significant positive impact on survival. This contrasts with previous reports, 2, 11 and suggests that tumour location and number are relevant when comparing survival outcomes for dogs with EL. In addition, dogs with multiple cutaneous lesions that experienced CR to therapy lived significantly longer compared to those that experienced PR or no response (SD or PD) to therapy. Clinically, this suggests that if there is an incomplete response to chosen chemotherapy (for example CCNU alone), it is worth continuing with other chemotherapy agents to try to achieve a CR, as that would be associated with longer survival.
In addition to responses to chemotherapy, a 42% ORR was reported for 14 dogs with cutaneous lymphoma (five with EL) treated with isotretinoin or etretinate for a median of 11 months. 15 Linoleic acid (in the form of safflower oil) resulted in clinical improvement in six of eight dogs with cutaneous EL for up to two years duration; 16 however, it was not clear whether these were CR or PR. The response rates and response duration for dogs receiving retinoids and/or linoleic acid were unable to be determined in this study; however, it was determined that dogs with multiple cutaneous EL treated with retinoids had a significantly longer MST (P = 0.001, Figure 3 ) that was independent of whether dogs received chemotherapy.
Radiotherapy can be used for local treatment or palliation for canine EL. 5 In a retrospective case series of 14 dogs with mucocutaneous oral lymphomas (of which 12 had EL) treated with coarse fractionation radiotherapy, the ORR was 67% with a MST of 770 days. 5 Radiation was part of treatment for 12 dogs in our study, but did not appear to influence survival times. Two dogs treated with radiation as a monotherapy for solitary mucosal lesions had long control of their disease (>700 days). Controlled studies using radiotherapy as primary therapy for the treatment of EL are indicated.
Surgery is an alternate option for solitary lesions with some dogs disease-free for longer than two years. solitary McM lesion developed new EL lesions more than five years (2,063 and 2,207 days, respectively) after the initial diagnosis.
The limitations of the present study were those typical for retrospective studies and included the lack of standardized treatment, monitoring and staging. Dogs were not randomized to receive various treatments, but rather such treatments depended on the choices of individual owners and attending veterinarians. Data collection may have been hindered by incomplete medical records. Thus, there is potential for flaws in the accuracy of information obtained. In addition, due to the retrospective nature of the study that spans over a period of 12 years, review of histological slides by a single person, and CD3 and CD79a immunohistochemistry could not be performed on all tumours to confirm EL.
Total time to progression (TTP) would have been an additional end-point to evaluate in this study, however was not able to be reliably determined, as the frequency of scheduled rechecks was not standardized in this study and there were many dogs where TTP could not be obtained. Therefore, we did not assess and perform statistical evaluations with TTP as an end-point. Survival was a more robust end-point, especially with the long followup data available and majority of dogs confirmed dead at the time the study concluded.
Lastly, we did not gather extensive chemotherapy toxicity data, as this was not a primary aim of our study. However, based on the data that were available, there appeared to be more VCOG-CTCAE grade 4 toxicity in dogs treated with VELCAP-EL combination chemotherapy compared to single-agent CCNU (Table S2 ). The toxicity is likely higher for dogs treated with VELCAP-EL combination chemotherapy because there were seven drugs used, and thus mathematically a greater risk for toxicity. However, combination chemotherapy should still be considered in dogs with EL that has not responded to CCNU, as CR to therapy was shown to be an independent predictor of longer survival in dogs with multiple cutaneous EL; in addition the use of multi-agent chemotherapy may increase the chances of obtaining CR.
In conclusion, based on survival times of dogs in this study, we suggest that EL in dogs may be clinically separated into a cutaneous form and an McM form of the disease. The occurrence of solitary lesions also confers an improved prognosis and was more commonly seen in the McM form of EL. Dogs with multiple cutaneous lesions appear to benefit from receiving chemotherapy, and/or retinoid treatment, with those attaining a CR to therapy having better survival times. This study suggests that the diagnosis of EL does not uniformly confer a poor prognosis and that the above prognostic factors should be evaluated in individual cases to assess their chances for longer survival and potential for benefit with different treatment options.
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Resumen
Introducci on -Se dispone de informaci on limitada sobre el tratamiento y los resultados de perros con linfoma epiteliotr opico. La enfermedad t ıpicamente tiene un mal pron ostico. Objetivos -Caracterizar los signos cl ınicos, identificar los factores pron osticos y evaluar el resultado del tratamiento de los perros con linfoma epiteliotr opico. M etodos -Una revisi on retrospectiva de los historiales cl ınicos de 2003 a 2015. Detalles del tratamiento, la respuesta del tumor y el tiempo de supervivencia estaban disponibles para 148 perros. Se evaluaron los posibles factores pron osticos para determinar su efecto estad ıstico sobre el tiempo medio de supervivencia. Resultados -El tiempo medio de supervivencia global para perros fue de 264 d ıas (cut aneo: 130 d ıas, mucocut aneo / mucoso: 491 d ıas). En an alisis multivariado, se asoci o la mediana del tiempo de supervivencia m as corta con la forma cut anea (P < 0,001) y la presencia de m ultiples lesiones (P < 0,001). Entre 80 perros con lesiones cut aneas, el tener tratamiento de quimioterapia (P < 0,001) y una lesi on solitaria (P < 0,001) se asociaron con una mayor mediana de supervivencia. En 72 perros con lesiones cut aneas m ultiples, la intervenci on quimioterap eutica (P < 0,001), el tratamiento con retinoides (P = 0,001) y la remisi on completa (P = 0,001) se asociaron con una mayor mediana de supervivencia. En 68 perros con lesiones mucocut aneas / de mucosas, una menor edad (P = 0,020) y lesi on solitaria (P = 0,015) se asociaron con una mediana de supervivencia m as prolongada. Conclusi on -El linfoma epiteliotr opico canino puede dividirse en formas cut anea y mucocut anea / de mucosas. Las lesiones solitarias tienen un mejor pron ostico. Los perros con lesiones m ultiples parecen beneficiarse de la quimioterapia y el tratamiento con retinoides, y aquellos que alcanzan la remisi on completa presentan mayor tiempos de supervivencia. La quimioterapia con agentes m ultiples podr ıa considerarse en perros con lesiones cut aneas que no responden a la quimioterapia con un solo agente. Tage) . In der multivariaten Analyse zeigte sich eine k€ urzere mediane € Uberlebensdauer bei der kutanen Form (P < 0,001) und beim Auftreten von multiplen L€ asionen (P < 0,001). Unter 80 Hunden mit kutanen L€ asionen wurde eine chemotherapeutische Behandlung (P < 0,001) und das Auftreten einer solit€ aren L€ asion (P < 0,001) mit einer l€ angeren medianen € Uberlebenszeit gesehen. Bei 72 Hunden mit multiplen kutanen Ver€ anderungen wurde eine l€ angere mediane € Uberlebenszeit nach chemotherapeutischer Behandlung (P < 0,001), Behandlung mit Retinoiden (P = 0,001) und nach kompletter Remission (P = 0,001) gesehen. Bei 68 Hunden mit mucokutanen/muk€ osen Ver€ anderungen, abnehmendem Alter (P = 0,020) und solit€ aren L€ asionen (P = 0,015) wurde eine l€ angere mediane € Uberlebenszeit festgestellt. Schlussfolgerungen -Das Epitheliotrope Lymphom des Hundes kann in kutane und mucocutane/muk€ ose Formen eingeteilt werden. Solit€ are Ver€ anderungen haben eine bessere Prognose. Hunde mit multiplen Ver€ anderungen scheinen von einer chemotherapeutischen Behandlung und von einer Behandlung mit Retinoiden zu profitieren, wobei jene, die eine komplette Remission erzielen l€ angere € Uberlebenszeiten haben. Eine multimodale Chemotherapie sollte bei Hunden mit kutanen L€ asionen erwogen werden, die nicht auf eine Chemotherapie mit einem einzelnen Agens ansprechen. 要約 背景 -上皮向性リンパ腫を有する犬に関する治療および予後に関した情報は限られている。この疾患 は、一般的に予後不良である。 目的 -上皮向性リンパ腫を有する犬の臨床症状を特徴付け、予後因子を同定し、治療効果を評価するこ と。 方法 -2003年から2015年までの診療記録の回顧的評価。148頭の犬について、治療の詳細、腫瘍の治療反 応性および生存時間が記録された。潜在的な予後因子については、生存期間中央値に対する統計学的効 果として評価した。 結果 -全体的な生存期間中央値は264日(皮膚:130日、皮膚粘膜/粘膜:491日)であった。 多変量解析では、 皮膚型(P < 0.001)および多発性病変の存在(P < 0.001)がより短い生存期間中央値と関連していた。皮膚病 変を有する80頭の犬のうち、化学療法(P < 0.001)および孤立性病変(P < 0.001)は、より長い生存期間中央 値と関連していた。多発性皮膚病変を有する72頭の犬において、化学療法(P < 0.001)、レチノイド治療 (P = 0.001)および完全寛解(P = 0.001)は、より長い生存期間中央値と関連していた。皮膚粘膜病変を有す る68匹の犬において、年齢の減少(P = 0.020)および孤立性病変(P = 0.015)は、より長い生存期間中央値と 関連していた。 結論 -犬の上皮向性リンパ腫は、皮膚型および粘膜皮膚/粘膜型に分類され得る。孤立性病変はより良好 な予後を有する。複数の病変を有する犬は化学療法およびレチノイド治療の恩恵を受ける傾向にあり、 完全寛解に達する犬はより長い生存時間を有する。多剤化学療法は、単一薬剤化学療法に反応しない皮 膚病変を有する犬において考慮され得る。 摘要 背景 -关于犬趋上皮性淋巴瘤的治疗和转归的资料比较少。该病普遍预后不良。 目标 -确定犬趋上皮性淋巴瘤的临床特点、预后因素并评估治疗效果。 方法 -回顾2003年至2015年病历记录。记录中找到148只犬的治疗细节、肿瘤反应和生存时间。评估可能 的预后因素对中位生存时间的统计学影响。 结果 -犬的总体中位生存时间为264天(皮肤:130天;粘膜皮肤/粘膜:491天)。在多变量分析中,较短的中位生 存时间与皮肤形态(P < 0.001)和多发性病变相关(P < 0.001)。在80例皮肤病变犬中,化疗(P < 0.001)和单个
